Table 1. Summary of the clinico-histopathological variables for 201 breast cancers studied using flow cytometry for tumour DNA content.
| |
N |
% |
|---|---|---|
| All | 201 | |
|
DNA content | ||
| Low | 79 | 39.3 |
| Intermediate | 42 | 20.8 |
| High | 23 | 11.4 |
| Mixed |
57 |
28.3 |
|
Tumour grade | ||
| 1 | 23 | 11.4 |
| 2 | 79 | 39.3 |
| 3 | 94 | 46.8 |
| Missing |
5 |
2.5 |
|
ER status | ||
| Negative | 48 | 23.9 |
| Positive | 152 | 75.6 |
| Missing |
1 |
0.5 |
|
PgR status | ||
| Negative | 89 | 44.3 |
| Positive | 111 | 55.2 |
| Missing |
1 |
0.5 |
|
HER2 status | ||
| Negative | 170 | 84.6 |
| Positive | 28 | 13.9 |
| Missing |
3 |
1.5 |
|
p53
status | ||
| Wild type | 146 | 72.6 |
| Mutant |
55 |
27.4 |
|
Survival status | ||
| Alive | 163 | 81.1 |
| Dead |
38 |
18.9 |
|
S-phase fraction | ||
| Low | 105 | 52.2 |
| Medium | 41 | 20.4 |
| High | 55 | 27.4 |
Abbreviations: ER, oestrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2.